After decades of setbacks, Alzheimer’s drug development is expanding beyond anti-amyloids, with a record number of trials and ...

Pinpointing who will and won’t get Alzheimer’s disease is tricky for doctors, but new research suggests it may soon get ...

What exactly is Alzheimer’s disease, and how common is it? A: Alzheimer’s disease is a neurodegenerative disease that causes dementia. It is caused in part by the accumulation of abnormally folded ...

The FDA expanded the uses of GE HealthCare’s Vizamyl imaging agent for highlighting the presence of beta amyloid proteins in the brain, with new green lights that enable more objective sc | The ...

Dr. Nicholas Milano of Medical University of SC says medications such as Lecanemab and donanemab give Alzheimer's patients ...

The revised label expands the brain-scan agent's use, and means that Vizamyl can now be used to diagnose Alzheimer's and predict the development of dementia due to disease, the company said. The ...

We were surprised to see the effect only in the Alzheimer’s spectrum and not in other neurodegenerative diseases." ...

The herb rosemary has been linked with memory—now researchers turned the compound against Alzheimer’s disease and cognitive ...

It would help the trials—and patients—if more people were tested for Alzheimer’s earlier on, so that they could be enrolled to try the new drugs. A single register of those with the disease would also ...

Anti-amyloid medications can help treat people in the early stages of Alzheimer’s by removing amyloid plaques from the brain. Although they’re not a cure for Alzheimer’s, they may help slow ...

A team of scientists including UCL researchers has tested four anti-amyloid Alzheimer's therapeutics to find out how the drugs bind to toxic amyloid beta protein to tackle the disease. Using new ...